Molecular and Metabolic Imaging of Castration-Resistant Prostate Cancer: State of Art and Future Prospects

doi:10.2174/1566524021666210211112423
摘要

前列腺癌(PCa)是西方国家男性最常见的肿瘤，也是最相关的死亡原因之一。雄激素剥夺疗法(ADT)是一种广泛应用于晚期前列腺癌的治疗方法。当前列腺癌进展，尽管ADT和阉割水平睾酮，严重的临床条件称为转移性阉割抵抗前列腺癌(mCRPC)发生。治疗mCRPC的唯一方法是以紫杉烷类化疗为代表多年。然而，最近引入的治疗方法，如第二代抗雄激素(如enzalutamide和abiraterone)、sipuleucel-T细胞免疫治疗或223ra -二氯靶向α治疗，显著改变了mCRPC的预后。这些新颖的治疗方法需要一种尚未满足的成像生物标志物，用于患者治疗前的分层和反应评估。在这种情况下，核医学可以提供多种代谢和分子探针来研究细胞和亚细胞水平的病理过程。本文的目的是回顾到目前为止发表的有关这一主题的文献中最相关的发现，特别强调每种示踪剂的优点和缺点，并涵盖定义个性化治疗方法的未来前景。
关键词: 前列腺癌，去势抵抗，抗雄激素，雄激素受体，18f -胆碱，骨扫描，18氟氯胺，前列腺特异性膜抗原。
« Previous Next »
[1] 
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin  2020; 70(1): 7-30.
[http://dx.doi.org/10.3322/caac.21590] [PMID:  31912902] 
[2] 
Lam TBL, MacLennan S, Willemse PM, et al. EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study). Eur Urol  2019; 76(6): 790-813.
[http://dx.doi.org/10.1016/j.eururo.2019.09.020] [PMID:  31587989] 
[3] 
Rodrigues G, Warde P, Pickles T, et al. Genitourinary Radiation Oncologists of Canada. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J  2012; 6(2): 121-7.
[http://dx.doi.org/10.5489/cuaj.11085] [PMID:  22511420] 
[4] 
Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes  2007; 14(3): 247-54.
[http://dx.doi.org/10.1097/MED.0b013e32814db88c] [PMID:  17940447] 
[5] 
Huang Y, Jiang X, Liang X, Jiang G. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett  2018; 15(5): 6063-76.
[http://dx.doi.org/10.3892/ol.2018.8123] [PMID:  29616091] 
[6] 
Shapiro D, Tareen B. Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther  2012; 12(7): 951-64.
[http://dx.doi.org/10.1586/era.12.59] [PMID:  22845410] 
[7] 
Rosino A, Ballester I, Tudela J, González-Billalabeitia E. Chemotherapy in metastatic castration resistant prostate cancer. Arch Esp Urol  2018; 71(8): 676-84.
[PMID:  30319127] 
[8] 
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol  2015; 4(3): 365-80.
[PMID:  26814148] 
[9] 
Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci  2012; 8(5): 767-75.
[http://dx.doi.org/10.5114/aoms.2012.31610] [PMID:  23185184] 
[10] 
El-Amm J, Aragon-Ching JB. Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets Ther  2015; 8: 1103-9.
[http://dx.doi.org/10.2147/OTT.S44291] [PMID:  26056474] 
[11] 
Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel)  2020; 12(6): 1367.
[http://dx.doi.org/10.3390/cancers12061367] [PMID:  32466595] 
[12] 
Schillaci O, Urbano N. Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium. Eur J Nucl Med Mol Imaging  2017; 44(4): 563-6.
[http://dx.doi.org/10.1007/s00259-017-3616-5] [PMID:  28083691] 
[13] 
Qin C, Ma X, Tian J. Translational research of optical molecular imaging for personalized medicine. Curr Mol Med  2013; 13(10): 1579-90.
[http://dx.doi.org/10.2174/1566524013666131111123201] [PMID:  24206134] 
[14] 
Filippi L, Scopinaro F, Pelle G, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imaging  2016; 43(3): 432-40.
[http://dx.doi.org/10.1007/s00259-015-3178-3] [PMID:  26323577] 
[15] 
Crawford ED, Stone NN, Yu EY, et al. Prostate Cancer
	Radiographic Assessments for Detection of Advanced
	Recurrence (RADAR) Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology  2014; 83(3): 664-9.
[http://dx.doi.org/10.1016/j.urology.2013.10.026] [PMID:  24411213] 
[16] 
Crawford ED, Petrylak DP, Shore N, et al. Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology  2017; 104: 150-9.
[http://dx.doi.org/10.1016/j.urology.2016.12.033] [PMID:  28302580] 
[17] 
Crawford ED, Koo PJ, Shore N, et al. RADAR III Group. A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol  2019; 201(4): 682-92.
[http://dx.doi.org/10.1016/j.juro.2018.05.164] [PMID:  30077557] 
[18] 
Townsend DW. Multimodality imaging of structure and function. Phys Med Biol  2008; 53(4): R1-R39.
[http://dx.doi.org/10.1088/0031-9155/53/4/R01] [PMID:  18263942] 
[19] 
Filippi L, Biancone L, Petruzziello C, Schillaci O. Tc-99m HMPAO-labeled leukocyte scintigraphy with hybrid SPECT/CT detects perianal fistulas in Crohn disease. Clin Nucl Med  2006; 31(9): 541-2.
[http://dx.doi.org/10.1097/01.rlu.0000233082.89996.3a] [PMID:  16921278] 
[20] 
Sonni I, Baratto L, Park S, et al. Initial experience with a SiPM-based PET/CT scanner: Influence of acquisition time on image quality. EJNMMI Phys  2018; 5(1): 9.
[http://dx.doi.org/10.1186/s40658-018-0207-x] [PMID:  29666972] 
[21] 
Alberts I, Prenosil G, Sachpekidis C, et al. Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: A matched-pair comparison. Eur J Nucl Med Mol Imaging  2020; 47(3): 614-23.
[http://dx.doi.org/10.1007/s00259-019-04630-y] [PMID:  31792572] 
[22] 
Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: Mechanisms and applications. J Nucl Med  2013; 54(4): 590-9.
[http://dx.doi.org/10.2967/jnumed.112.114298] [PMID:  23482667] 
[23] 
Einhorn TA, Vigorita VJ, Aaron A. Localization of technetium-99m methylene diphosphonate in bone using microautoradiography. J Orthop Res  1986; 4(2): 180-7.
[http://dx.doi.org/10.1002/jor.1100040206] [PMID:  3712127] 
[24] 
Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res  1998; 4(7): 1765-72.
[PMID: 9676853] 
[25] 
Dennis ER, Jia X, Mezheritskiy IS, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol  2012; 30(5): 519-24.
[http://dx.doi.org/10.1200/JCO.2011.36.5791] [PMID:  22231045] 
[26] 
Song H, Jin S, Xiang P, Hu S, Jin J. Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. BMC Cancer  2020; 20(1): 238.
[http://dx.doi.org/10.1186/s12885-020-06739-y] [PMID:  32197590] 
[27] 
Jadvar H, Desai B, Conti PS. Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. Semin Nucl Med  2015; 45(1): 58-65.
[http://dx.doi.org/10.1053/j.semnuclmed.2014.07.008] [PMID:  25475379] 
[28] 
Apolo AB, Lindenberg L, Shih JH, et al. Prospective study evaluating Na18F PET/CT in predicting clinical outcomes and survival in advanced prostate cancer. J Nucl Med  2016; 57(6): 886-92.
[http://dx.doi.org/10.2967/jnumed.115.166512] [PMID:  26795292] 
[29] 
Zukotynski KA, Kim CK, Gerbaudo VH, et al. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging  2014; 5(1): 72-82.
[PMID: 25625029] 
[30] 
Kairemo K, Joensuu T. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Diagnostics (Basel)  2015; 5(4): 413-27.
[http://dx.doi.org/10.3390/diagnostics5040413] [PMID:  26854163] 
[31] 
Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci  2016; 41(3): 211-8.
[http://dx.doi.org/10.1016/j.tibs.2015.12.001] [PMID:  26778478] 
[32] 
Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The Metabolic Phenotype of Prostate Cancer. Front Oncol  2017; 7: 131.
[http://dx.doi.org/10.3389/fonc.2017.00131] [PMID:  28674679] 
[33] 
Vaz CV, Alves MG, Marques R, et al. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol  2012; 44(11): 2077-84.
[http://dx.doi.org/10.1016/j.biocel.2012.08.013] [PMID:  22964025] 
[34] 
Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun  2020; 41(1): 78-86.
[http://dx.doi.org/10.1097/MNM.0000000000001123] [PMID:  31800510] 
[35] 
Bauckneht M, Capitanio S, Donegani MI, et al. Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223. Cancers (Basel)  2019; 12(1)E31
[http://dx.doi.org/10.3390/cancers12010031] [PMID:  31861942] 
[36] 
Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem  1994; 269(5): 3858-67.
[http://dx.doi.org/10.1016/S0021-9258(17)41939-9] [PMID:  8106431] 
[37] 
Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol  2004; 31(7): 859-65.
[http://dx.doi.org/10.1016/j.nucmedbio.2004.05.002] [PMID:  15464387] 
[38] 
Calabria F, Chiaravalloti A, Cicciò C, et al. PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl Med Biol  2017; 51: 40-54.
[http://dx.doi.org/10.1016/j.nucmedbio.2017.04.004] [PMID:  28575697] 
[39] 
Nozaki K, Kawai T, Fujimura T, et al. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer. Int Urol Nephrol  2019; 51(10): 1763-9.
[http://dx.doi.org/10.1007/s11255-019-02233-y] [PMID:  31325132] 
[40] 
De Giorgi U, Caroli P, Scarpi E, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging  2015; 42(8): 1276-83.
[http://dx.doi.org/10.1007/s00259-015-3042-5] [PMID:  25808631] 
[41] 
Lee J, Sato MM, Coel MN, Lee KH, Kwee SA. Prediction of PSA progression in castration-resistant prostate cancer based on treatment-associated change in tumor burden quantified by 18F-fluorocholine PET/CT. J Nucl Med  2016; 57(7): 1058-64.
[http://dx.doi.org/10.2967/jnumed.115.169177] [PMID:  26912444] 
[42] 
Caroli P, De Giorgi U, Scarpi E, et al. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Eur J Nucl Med Mol Imaging  2018; 45(3): 348-54.
[http://dx.doi.org/10.1007/s00259-017-3866-2] [PMID:  29110067] 
[43] 
Filippi L, Basile P, Schillaci O, Bagni O. The relationship between total lesion activity on 18F choline positron emission tomography-computed tomography and clinical outcome in patients with castration-resistant prostate cancer bone metastases treated with 223Radium. Cancer Biother Radiopharm  2020; 35(6): 398-403.
[http://dx.doi.org/10.1089/cbr.2019.3188] [PMID:  32109140] 
[44] 
Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med  2007; 48(3): 420-8.
[PMID: 17332620] 
[45] 
Almeida FD, Yen CK, Scholz MC, et al. Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer. Am J Nucl Med Mol Imaging  2017; 7(1): 1-11.
[PMID: 28123863] 
[46] 
Yu EY, Muzi M, Hackenbracht JA, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med  2011; 36(3): 192-8.
[http://dx.doi.org/10.1097/RLU.0b013e318208f140] [PMID:  21285676] 
[47] 
Farnebo J, Wadelius A, Sandström P, et al. Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT. Medicine (Baltimore)  2016; 95(31)e4308
[http://dx.doi.org/10.1097/MD.0000000000004308] [PMID:  27495034] 
[48] 
Karanikas G, Beheshti M. 11C-acetate PET/CT imaging: physiologic uptake, variants, and pitfalls. PET Clin  2014; 9(3): 339-44.
[http://dx.doi.org/10.1016/j.cpet.2014.03.006] [PMID:  25030397] 
[49] 
Parent EE, Schuster DM. Update on 18F-Fluciclovine PET for Prostate Cancer Imaging. J Nucl Med  2018; 59(5): 733-9.
[http://dx.doi.org/10.2967/jnumed.117.204032] [PMID:  29523631] 
[50] 
Segawa A, Nagamori S, Kanai Y, Masawa N, Oyama T. L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer. Mol Clin Oncol  2013; 1(2): 274-80.
[http://dx.doi.org/10.3892/mco.2012.54] [PMID:  24649160] 
[51] 
Laudicella R, Albano D, Alongi P, et al. on the behalf of Young AIMN working group. 18F-Facbc in prostate cancer: a systematic review and meta-analysis. Cancers (Basel)  2019; 11(9)E1348
[http://dx.doi.org/10.3390/cancers11091348] [PMID:  31514479] 
[52] 
Okudaira H, Oka S, Ono M, et al. Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol  2014; 16(6): 756-64.
[http://dx.doi.org/10.1007/s11307-014-0756-x] [PMID:  24943499] 
[53] 
Amorim BJ, Prabhu V, Marco SS, et al. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging  2020; 47(1): 105-14.
[http://dx.doi.org/10.1007/s00259-019-04506-1] [PMID:  31492992] 
[54] 
Chang SS. Overview of prostate-specific membrane antigen. Rev Urol  2004; 6(S10)(Suppl. 10): S13-8.
[PMID: 16985927] 
[55] 
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer  1998; 82(11): 2256-61.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2256:AID-CNCR22>3.0.CO;2-S] [PMID:  9610707] 
[56] 
Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer  1998; 83(4): 739-47.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19980815)83:4<739:AID-CNCR16>3.0.CO;2-T] [PMID:  9708939] 
[57] 
Leung K. 111In-Capromab PendetideMolecular Imaging and Contrast Agent Database (MICAD) Bethesda (MD). National Center for Biotechnology Information (US)  2004.
[58] 
Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology  1999; 54(6): 1058-63.
[http://dx.doi.org/10.1016/S0090-4295(99)00314-3] [PMID:  10604708] 
[59] 
Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate  1998; 37(4): 261-9.
[http://dx.doi.org/10.1002/(SICI)1097-0045(19981201)37:4<261:AID-PROS8>3.0.CO;2-#] [PMID:  9831223] 
[60] 
Nagda SN, Mohideen N, Lo SSV, et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys  2007; 67(3): 834-40.
[http://dx.doi.org/10.1016/j.ijrobp.2006.09.026] [PMID:  17293236] 
[61] 
Filippi L, Schillaci O. SPECT/CT with a hybrid camera: a new imaging modality for the functional anatomical mapping of infections. Expert Rev Med Devices  2006; 3(6): 699-703.
[http://dx.doi.org/10.1586/17434440.3.6.699] [PMID:  17280534] 
[62] 
Hardie AD, Rieter WJ, Bradshaw ML, Gordon LL, Young MA, Keane TE. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol  2013; 31(6): 1327-32.
[http://dx.doi.org/10.1007/s00345-013-1079-2] [PMID:  23595605] 
[63] 
Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med  2019; 60(6): 786-93.
[http://dx.doi.org/10.2967/jnumed.118.219501] [PMID:  30530831] 
[64] 
Fourquet A, Aveline C, Cussenot O, et al. 68Ga-PSMA-11 PET/CT in Restaging Castration-Resistant Nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact. Sci Rep  2020; 10(1): 2104.
[http://dx.doi.org/10.1038/s41598-020-58975-8.] 
[65] 
Rosar F, Dewes S, Ries M, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging  2020; 47(3): 687-94.
[http://dx.doi.org/10.1007/s00259-019-04674-0] [PMID:  31901103] 
[66] 
Heck MM, Tauber R, Schwaiger S, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol  2019; 75(6): 920-6.
[http://dx.doi.org/10.1016/j.eururo.2018.11.016] [PMID:  30473431] 
[67] 
Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med  2017; 58(1): 85-90.
[http://dx.doi.org/10.2967/jnumed.116.183194] [PMID:  27765862] 
[68] 
Poty S, Mandleywala K, O’Neill E, Knight JC, Cornelissen B, Lewis JS. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics  2020; 10(13): 5802-14.
[http://dx.doi.org/10.7150/thno.44772] [PMID:  32483420] 
[69] 
Sathekge M, Bruchertseifer F, Knoesen O, et al. Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging  2019; 46(10): 1988.
[http://dx.doi.org/10.1007/s00259-019-04401-9] [PMID:  31240331] 
[70] 
Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J  1998; 17(18): 5497-508.
[http://dx.doi.org/10.1093/emboj/17.18.5497] [PMID:  9736627] 
[71] 
Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer  2011; 30(7): 463-71.
[http://dx.doi.org/10.5732/cjc.011.10111] [PMID:  21718592] 
[72] 
de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med  2020; 382(22): 2091-102.
[http://dx.doi.org/10.1056/NEJMoa1911440] [PMID:  32343890] 
[73] 
Zhou D, Xu J, Mpoy C, et al. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nucl Med Biol  2018; 66: 26-31.
[http://dx.doi.org/10.1016/j.nucmedbio.2018.08.003] [PMID:  30195072] 
[74] 
Wang B, Liu C, Wei Y, et al. A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res  2020; 26(17): 4551-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-0587] [PMID:  32527944] 
Rights & Permissions Print Cite
Article Metrics
19
3
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1566524021666210211112423	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666
当代分子医药

去势抵抗性前列腺癌的分子和代谢成像:最新进展和未来展望

摘要

当代分子医药

去势抵抗性前列腺癌的分子和代谢成像:最新进展和未来展望

摘要 Play Pause

Related Journals

Related Books

Related Articles

摘要
